Tia D Jeffery1, Matthew L Richardson2. 1. College of Agriculture, Urban Sustainability and Environmental Sciences, University of the District of Columbia, USA. 2. College of Agriculture, Urban Sustainability and Environmental Sciences, University of the District of Columbia, USA. Electronic address: matthew.richardson@udc.edu.
Abstract
ETHNOPHARMACOLOGICAL RELEVANCE: Hibiscus species (Family: Malvaceae) have long been used in traditional medicine to treat a variety of maladies such as abscesses, bilious conditions, cancer, cough, fatigue, gastrointestinal discomfort, fever, veisalgia, cardiovascular disorders, neurosis, scurvy, and urinary tract disorders. Its antioxidants have the capacity to destroy free radicals that damage cells and increase risk of inflammatory conditions such as metabolic syndrome, cancer, and cardiovascular disease. AIM OF THE STUDY: This review synthesizes findings from animal studies and clinical trials to assess effectiveness of hibiscus for treating biomarkers of metabolic syndrome including hyperglycemia, hypertriglyceridemia, low high-density lipoprotein, obesity, and hypertension. MATERIALS AND METHODS: We searched for 12 edible species of hibiscus in the Google Scholar database. Each scientific name of these species, their common names and their edible plant parts were searched in conjunction with fourteen key words associated with metabolic syndrome. A total of 68 articles met all inclusion criteria for this review, including 18 that tested human subjects, 48 that tested other animals, one that tested humans and other animals, and one that did not specify. RESULTS: Hibiscus often improved blood glucose, total cholesterol, high-density lipoprotein cholesterol, triglycerides, blood pressure, weight, lipid absorption and oxidation of fatty acids within vital organs around the abdominal cavity. Higher doses led to greater benefits in some cases, especially for body mass of animals, but lower doses were often equally effective. Hibiscus was often equally or more effective than pharmaceuticals in improving some biomarkers of metabolic syndrome, especially blood glucose and insulin sensitivity. CONCLUSION: Hibiscus shows great promise for improving biomarkers of metabolic syndrome, but there are limitations that need to be addressed by future work, including increasing the number and size of human clinical trials, expanding human trials to include people from a greater diversity of ethnicities, taking into account the health and physical activity of human participants, investigating the influence of growing conditions and extraction/preparation techniques on nutrients in hibiscus, comparing the efficacy of several plant parts and plant products of hibiscus to a reference control group within the same experiment, incorporating rigorous statistical analysis of treatments and investigating the influence of dosage.
ETHNOPHARMACOLOGICAL RELEVANCE: Hibiscus species (Family: Malvaceae) have long been used in traditional medicine to treat a variety of maladies such as abscesses, bilious conditions, cancer, cough, fatigue, gastrointestinal discomfort, fever, veisalgia, cardiovascular disorders, neurosis, scurvy, and urinary tract disorders. Its antioxidants have the capacity to destroy free radicals that damage cells and increase risk of inflammatory conditions such as metabolic syndrome, cancer, and cardiovascular disease. AIM OF THE STUDY: This review synthesizes findings from animal studies and clinical trials to assess effectiveness of hibiscus for treating biomarkers of metabolic syndrome including hyperglycemia, hypertriglyceridemia, low high-density lipoprotein, obesity, and hypertension. MATERIALS AND METHODS: We searched for 12 edible species of hibiscus in the Google Scholar database. Each scientific name of these species, their common names and their edible plant parts were searched in conjunction with fourteen key words associated with metabolic syndrome. A total of 68 articles met all inclusion criteria for this review, including 18 that tested human subjects, 48 that tested other animals, one that tested humans and other animals, and one that did not specify. RESULTS: Hibiscus often improved blood glucose, total cholesterol, high-density lipoprotein cholesterol, triglycerides, blood pressure, weight, lipid absorption and oxidation of fatty acids within vital organs around the abdominal cavity. Higher doses led to greater benefits in some cases, especially for body mass of animals, but lower doses were often equally effective. Hibiscus was often equally or more effective than pharmaceuticals in improving some biomarkers of metabolic syndrome, especially blood glucose and insulin sensitivity. CONCLUSION: Hibiscus shows great promise for improving biomarkers of metabolic syndrome, but there are limitations that need to be addressed by future work, including increasing the number and size of human clinical trials, expanding human trials to include people from a greater diversity of ethnicities, taking into account the health and physical activity of humanparticipants, investigating the influence of growing conditions and extraction/preparation techniques on nutrients in hibiscus, comparing the efficacy of several plant parts and plant products of hibiscus to a reference control group within the same experiment, incorporating rigorous statistical analysis of treatments and investigating the influence of dosage.
Authors: Elgloria Harrison; Lillie Monroe-Lord; Andrew D Carson; Anne Marie Jean-Baptiste; Janet Phoenix; Phronie Jackson; B Michelle Harris; Elmira Asongwed; Matthew L Richardson Journal: BMC Public Health Date: 2021-04-19 Impact factor: 3.295